Recent Updates
Recently added Catalysts
BCDA

BioCardia to Present at 2015 Stem Cell Meeting on the Mesa

Key Takeaway: SAN CARLOS, Calif., Oct. 05, 2015 (GLOBE NEWSWIRE) -- BioCardia, Inc., a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases announced today that Peter Altman, Chief Executive Officer will present at the annual Partnering Forum o

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+2%
120-day peak, hindsight
Typical move
19.6%
average across 4 past catalysts
Cash runway
~7 mo
Medium dilution risk
Lead asset
Autologous cell therapy
Phase 3 · Heart Failure, Systolic

Full Press Release Details

SAN CARLOS, Calif., Oct. 05, 2015 (GLOBE NEWSWIRE) -- BioCardia, Inc., a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases announced today that Peter Altman, Chief Executive Officer will present at the annual Partnering Forum of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, California.
Event: 2015 Stem Cell Meeting on the Mesa – Partnering Forum
Date: October 07, 2015
Time: 1:30 p.m. PDT
Location: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037
A live video webcast will be available at: http://stemcellmeetingonthemesa.com/webcast/.
Please visit http://stemcellmeetingonthemesa.com/ for full information.
This conference brings together senior executives and top decision makers in the industry within the scientific community with the shared goal of advancing and translating cutting-edge research into revolutionary treatments and cures.
BioCardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its CardiAMP™ and CardiALLO™ cell therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. These programs are enabled by the Company's Helix™ transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.
For additional information visit www.BioCardia.com.
Last updated: Oct 6, 2015